203 related articles for article (PubMed ID: 28797244)
1. A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
Ben Younes K; Body S; Costé É; Viailly PJ; Miloudi H; Coudre C; Jardin F; Ben Aissa-Fennira F; Sola B
BMC Cancer; 2017 Aug; 17(1):538. PubMed ID: 28797244
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
3. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
Bogner C; Peschel C; Decker T
Leuk Lymphoma; 2006 Feb; 47(2):195-205. PubMed ID: 16321849
[TBL] [Abstract][Full Text] [Related]
4. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
[TBL] [Abstract][Full Text] [Related]
5. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.
Shishodia S; Amin HM; Lai R; Aggarwal BB
Biochem Pharmacol; 2005 Sep; 70(5):700-13. PubMed ID: 16023083
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.
de Vos S; Krug U; Hofmann WK; Pinkus GS; Swerdlow SH; Wachsman W; Grogan TM; Said JW; Koeffler HP
Diagn Mol Pathol; 2003 Mar; 12(1):35-43. PubMed ID: 12605034
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
Lo RK; Kwong YL
Ann Hematol; 2014 Feb; 93(2):255-65. PubMed ID: 23949314
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Pérez-Galán P; Mora-Jensen H; Weniger MA; Shaffer AL; Rizzatti EG; Chapman CM; Mo CC; Stennett LS; Rader C; Liu P; Raghavachari N; Stetler-Stevenson M; Yuan C; Pittaluga S; Maric I; Dunleavy KM; Wilson WH; Staudt LM; Wiestner A
Blood; 2011 Jan; 117(2):542-52. PubMed ID: 20956803
[TBL] [Abstract][Full Text] [Related]
10. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.
Mohanty A; Sandoval N; Das M; Pillai R; Chen L; Chen RW; Amin HM; Wang M; Marcucci G; Weisenburger DD; Rosen ST; Pham LV; Ngo VN
Oncotarget; 2016 Nov; 7(45):73558-73572. PubMed ID: 27713153
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.
Zhang L; Pham LV; Newberry KJ; Ou Z; Liang R; Qian J; Sun L; Blonska M; You Y; Yang J; Lin X; Rollo A; Tamayo AT; Lee J; Ford RJ; Zhao X; Kwak LW; Yi Q; Wang M
Mol Cancer Ther; 2013 Nov; 12(11):2494-504. PubMed ID: 23990113
[TBL] [Abstract][Full Text] [Related]
13. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
[TBL] [Abstract][Full Text] [Related]
15. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells.
Bogner C; Ringshausen I; Schneller F; Fend F; Quintanilla-Martinez L; Häcker G; Goetze K; Oostendorp R; Peschel C; Decker T
Br J Haematol; 2003 Jul; 122(2):260-8. PubMed ID: 12846895
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
18. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.
Guidoboni M; Zancai P; Cariati R; Rizzo S; Dal Col J; Pavan A; Gloghini A; Spina M; Cuneo A; Pomponi F; Bononi A; Doglioni C; Maestro R; Carbone A; Boiocchi M; Dolcetti R
Cancer Res; 2005 Jan; 65(2):587-95. PubMed ID: 15695403
[TBL] [Abstract][Full Text] [Related]
19. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
[TBL] [Abstract][Full Text] [Related]
20. The molecular pathogenesis of mantle cell lymphoma.
Vogt N; Dai B; Erdmann T; Berdel WE; Lenz G
Leuk Lymphoma; 2017 Jul; 58(7):1530-1537. PubMed ID: 27894215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]